SCHEMBL3676021

SCHEMBL3676021

CCCCOCCCNC(=O)c1ccc(N2CCN(C(=O)c3sccc3C)CC2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 2/20 0.44
ALDH1A1 P00352 5/20 0.43
HPGD P15428 3/20 0.43
NPC1 O15118 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
PKM P14618 1/20 0.43
USP30 Q70CQ3 2/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 1/20 0.42
POLB P06746 1/20 0.42
NAMPT P43490 1/20 0.41
KDM4E B2RXH2 1/20 0.41
FOLH1 Q04609 1/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671671 0.94 USP30 (0.45) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3670540 0.93 SCD (0.47) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3668860 0.91 SCD (0.46) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3672411 0.91 SCD (0.46) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3669208 0.89 SCD (0.48) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3667904 0.86 SCD (0.46) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3674482 0.85 SCD (0.50) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3672273 0.84 LMNA (0.54) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3670505 0.84 SCD (0.57) SCDALDH1A1HPGDNPC1TSHR
SCHEMBL3668937 0.83 SCD (0.46) SCDALDH1A1HPGDNPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT SCD 10/4885ALDH1A1 1127/4885HPGD 104/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 SCD 1186/4885ALDH1A1 3898/4885HPGD 3301/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT SCD 10/4885ALDH1A1 1127/4885HPGD 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.